← Back
Treatment and the treatment process

Consolidation

Consolidation is the phase after remission. Its goal is to destroy leukemia cells that cannot be seen in tests but may remain in the body.

Last updated: ~2 min read
Hair-thin cracks in a dark navy stone surface gently sealed by threads of golden light.
Figure 1.Consolidation strengthens the remission.

01Short answer

Even when remission is reached after induction, millions of invisible leukemia cells may remain in the body. Consolidation (sometimes called "intensification" or "post-remission therapy") reduces them and lowers the risk of relapse. In AML it is usually 3–4 courses of intermediate- or high-dose cytarabine, sometimes with a targeted drug, or, if the risk is high, an allogeneic stem cell transplant. In ALL it is a complex plan of different drug blocks over several months, followed by long maintenance therapy. Blood counts fall again between courses, but some courses can be given partly as an outpatient. Decisions are based on MRD results and the risk group.

02Simple explanation

Why is it needed? Remission means "visible" leukemia has gone, but hidden cells may remain.

How? Several extra courses or a transplant.

How long? Usually several months.

Breaks. Time to recover is given between courses.

03Scientific explanation

Residual disease: even in complete remission, up to 10⁸–10⁹ leukemia cells may remain in the marrow; MRD tests (flow cytometry, PCR, NGS) measure them with a sensitivity of 10⁻⁴–10⁻⁶ (NCI).

AML: with favourable risk, courses of high-dose cytarabine; with intermediate/adverse risk or MRD positivity, an allogeneic transplant in first remission (ESMO, ELN). With an FLT3 mutation, midostaurin or quizartinib may be added to the courses.

ALL: consists of blocks of consolidation, delayed intensification and CNS prevention; blinatumomab is used in MRD-positive B-ALL.

04What happens in the body?

How do the courses go?

Each course lasts a few days, followed by 3–5 weeks of recovery. With high-dose cytarabine, steroid eye drops protect the eyes, and neurological signs such as balance and speech are monitored.

Evenly spaced rings of teal and gold light on a dark background.
Figure 3.Consolidation means repeated courses over months.

Transplant or chemotherapy?

The decision depends on the leukemia’s genetics, MRD, donor availability and general health. A transplant can lower the relapse risk further but carries serious risks of its own.

Under a magnifying glass over healthy blood cells, a few hidden cells glow faintly red.
Figure 2.MRD reveals hidden residual cells.

Life between courses

You may be able to stay at home during recovery. The rules on infection protection, food safety and calling straight away with a fever still apply.

05The consolidation path

A simplified outline.

Remission — After induction.1RemissionAfter induction.
Risk and MRD — Choosing the plan.2Risk and MRDChoosing the plan.
Courses — Chemotherapy or transplant.3CoursesChemotherapy or transplant.
Next — Maintenance or follow-up.4NextMaintenance or follow-up.
Deeper remissionMRD falls.
Personal planBy risk.
TeamSupport between courses.

06Consolidation options (simplified)

OptionFor whom?Note
High-dose cytarabineAML, favourable risk3–4 courses
Targeted add-onFLT3 mutationMidostaurin, quizartinib
Allogeneic transplantHigh risk, MRD+In first remission
ALL blocksALLSeveral months
BlinatumomabMRD+ B-ALLSeparate courses
Continuing a gentle regimenOlder peopleAzacitidine + venetoclax continued

* Your doctor sets the exact plan.

07Key terms

Consolidation
The phase that strengthens remission.
Post-remission therapy
Treatment after remission.
MRD
Measurable residual disease.
Relapse
The leukemia coming back.
Allogeneic transplant
A stem cell transplant from a donor.
Cerebellar toxicity
The effect of high-dose cytarabine on balance.

08Key points

  • Remission is not the end of treatment.
  • Consolidation destroys hidden cells.
  • The plan depends on risk and MRD.
  • Not everyone needs a transplant.
  • Recovery between courses matters.
  • Call straight away with a fever.

09Frequently asked questions

How many courses will there be?

Usually 3–4 in AML, and by protocol in ALL; your doctor will tell you exactly.

Can I work between courses?

Some people do light work; discuss the infection risk with your doctor.

What does MRD-positive mean?

A small number of leukemia cells is still present; this may change the plan.

Can I decline consolidation?

That greatly increases the risk of relapse; the decision should be discussed in detail with your doctor.

10Questions for your doctor

Take these questions to your appointment. The ones you save are collected on the “My questions” page and stay on this device only.

  1. How many courses will there be?

  2. Can I work between courses?

  3. What does MRD-positive mean?

  4. Can I decline consolidation?

My questions

12Sources

  1. National Cancer Institute (NCI). Adult Acute Myeloid Leukemia Treatment (PDQ) – Patient Version
  2. National Cancer Institute (NCI). Adult Acute Lymphoblastic Leukemia Treatment (PDQ) – Patient Version
  3. National Cancer Institute (NCI). Chemotherapy to Treat Cancer
  4. Cancer Research UK. Chemotherapy
  5. American Cancer Society. Typical Treatment of Acute Myeloid Leukemia (Except APL)
  6. Blood Cancer United (LLS). Acute myeloid leukemia (AML) treatment: phases of treatment
  7. MedlinePlus. Dialysis
  8. MedlinePlus. Diabetes Type 1
  9. MedlinePlus. Diabetes Medicines
  10. MedlinePlus. Diabetes Type 2
Medical disclaimerThis information is for educational purposes only and does not replace medical advice.
Last updated: ← Back to the list

Open the interactive site →